[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-355959-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-355959-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","akr1b1-promotes-canine-mammary-tumorigenesis-via-activation-of-pi3kakt-signaling-and-acts-as-a-serum-biomarker","AKR1B1 promotes canine mammary tumorigenesis via activation of PI3K/AKT signaling and acts as a serum biomarker","","AKR1B1 (aldose reductase) is investigated as a driver of canine mammary tumorigenesis and as a circulating biomarker. AKR1B1 expression is assessed in paired CMT and adjacent normal tissues by immunohistochemistry, and CMT-U27 cells are manipulated using lentiviral overexpression or shRNA knockdown. AKR1B1 increases proliferation and migration while elevating phosphorylated AKT (Thr308) and downregulating P21/P27; knockdown reverses these effects. A magnetic-particle chemiluminescence immunoassay quantifies serum AKR1B1, revealing higher levels in CMT cases and ROC AUC 0.8386 for non-invasive diagnosis and monitoring.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/akr1b1-promotes-canine-mammary-tumorigenesis-via-activation-of-pi3kakt-signaling-and-acts-as-a-serum-biomarker/355959/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/akr1b1-promotes-canine-mammary-tumorigenesis-via-activation-of-pi3kakt-signaling-and-acts-as-a-serum-biomarker/355959.png","ImageObject",300,407,{"name":42,"@type":43},"Mary Man","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the central hypothesis of the study?","Question",{"text":63,"@type":64},"AKR1B1 is proposed to be overexpressed in canine mammary tumors, to promote tumor cell proliferation and migration via PI3K/AKT signaling, and to be detectable in serum as a circulating biomarker.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does AKR1B1 affect PI3K/AKT signaling and cell-cycle regulators?",{"text":68,"@type":64},"AKR1B1 overexpression increases phosphorylated AKT (Thr308) and downregulates P21 and P27, whereas AKR1B1 knockdown produces opposite effects.",{"name":70,"@type":61,"acceptedAnswer":71},"What diagnostic performance does serum AKR1B1 show for CMT?",{"text":72,"@type":64},"Serum AKR1B1 is significantly higher in canines with CMT than in healthy controls, and ROC analysis reports an AUC of 0.8386 with sensitivity 74.0% and specificity 83.9% at a 3.08 ng/mL cutoff.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},355959,1790194417,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":112,"preview_page_count":33,"preview_urls":145},7421720224475,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nAKR1B1 promotes canine mammary tumorigenesis via activation of PI3K/AKT signaling and acts as a serum biomarker  \nZhe Cao1, Qinyu Zhang2, Yujun Zhou1, Haoyu Li1, Deliang Cao3􀀍 & Zhiliang Sun1􀀍  \nAldo-keto reductase 1B1 (AKR1B1), also named as aldose reductase, is an enzyme implicated in metabolic regulation and signaling transduction in human cancers, but little is known in canine mammary tumors (CMTs). This study investigated expression inCMT tissues, functional role in tumor progression, and potential ofAKR1B1 as a circulating biomarker. AKR1B1 expression was evaluated by immunohistochemistry in paired CMT and adjacent normal mammary tissues, and CMT-U27  \ncells with lentiviralAKR1B1 overexpression or shRNA-mediated AKR1B1 knockdown were used for investigation of cell proliferation, migration, and Western blot analysis of PI3K/AKT signaling and cellcycle regulators. Results showed that AKR1B1 was markedly overexpressed inCMT tissues compared to adjacent normal glands. Targeted expression of AKR1B1 in CMT-U27 cells promoted proliferation, migration, accompanied by increase of phosphorylatedAKT (Thr308) and downregulation of P21 and P27, whereas AKR1B1 knockdown led to opposite effects. Magnetic-particle chemiluminescence immunoassay was developed to measure serum AKR1B1 concentrations, and results showed serum AKR1B1 was significantly higher in Canines with CMT (4.65 ± 0.37 ng/mL; n = 50) than in healthy controls (2.27 ± 0.15 ng/mL; n = 56) . Receiver operating characteristic analysis demonstrated impressive diagnostic performance with AUC = 0.8386 (95% CI 0.7597–0.9174), sensitivity at 74.0% and specificity at 83.9% at a cutoff of 3.08 ng/mL. These findings indicate that AKR1B1 acts as a tumorigenic driver via PI3K/AKT-mediated oncogenesis inCMT and a serum biomarker for non-invasive diagnosis of CMT and monitoring of disease progression.  \nKeywords AKR1B1, Canine mammary tumors, PI3K/AKT signaling, Serum biomarker, Cell proliferation  \nIn intact female Canines, canine mammary tumors (CMTs) are the most prevalent neoplasms, representing approximately 50–70% of all tumors in this population, and about half of CMTs are malignant with variable metastatic potential1,2. Owing to shared hormonal influences, histologic subtypes, and molecular features, CMTsare recognized as a spontaneous model for human breast cancer, offering valuable translational insight into tumor biology and therapy3–5. Despite this relevance, diagnosis still relies primarily on physical examination and imaging, as no validated serum biomarker for early detection or disease monitoring has been adopted in veterinary oncology.  \nAmong molecular pathways implicated in CMTs, dysregulation of PI3K/AKT signaling is one of the most frequent and functionally important. Overexpression and activation of PI3K/AKT/PTEN components correlate with high histologic grade and aggressive behavior6, and pharmacologic inhibition of this pathway suppresses proliferation and induces apoptosis in CMT cell lines7. Activating PIK3CA mutations, including hotspot variants such as H1047R, have also been detected in CMT tissues and explored as liquid-biopsy targets8. However, upstream metabolic regulators converging on PI3K/AKT signaling remain poorly defined in the canine context.  \n1China Collaborative Innovation for Ultilization of Botanical Function Ingredients, Hunan Engineering Technology Research Center of Veterinary Drugs, Hunan Agricultural University Veterinary Faculty, Changsha 410128, China.  \n2Science and Technology Innovation Center, Hunan University of Chinese Medicine, Changsha 410208, China.  \n3Hunan Province Key Laboratory of Tumor Cellular & Molecular Pathology, Cancer Research Institute, Hengyang Medical School, University of South China, Hengyang 421001, Hunan, China. 􀀍 email: [dcao@usc.edu.cn](dcao@usc.edu.cn); [sunzhiliang1965@aliyun.com](sunzhiliang1965@aliyun.com)  \nThe aldo-keto reduct","cbCaiaw318bcETe5","https://ap.wps.com/l/cbCaiaw318bcETe5","pdf",2496420,12,"English","# Introduction\n## Canine mammary tumors and current diagnostic needs\n## PI3K/AKT pathway in tumor biology\n# Methods and Experimental Design\n## AKR1B1 expression in tissues\n## Cell model manipulation and signaling assays\n## Serum AKR1B1 measurement by immunoassay\n# Results\n## AKR1B1 overexpression in CMT tissues\n## Effects on proliferation, migration, and PI3K/AKT-P21/P27\n## Diagnostic performance of serum AKR1B1\n# Conclusion and Implications","[{\"question\":\"What is the central hypothesis of the study?\",\"answer\":\"AKR1B1 is proposed to be overexpressed in canine mammary tumors, to promote tumor cell proliferation and migration via PI3K/AKT signaling, and to be detectable in serum as a circulating biomarker.\"},{\"question\":\"How does AKR1B1 affect PI3K/AKT signaling and cell-cycle regulators?\",\"answer\":\"AKR1B1 overexpression increases phosphorylated AKT (Thr308) and downregulates P21 and P27, whereas AKR1B1 knockdown produces opposite effects.\"},{\"question\":\"What diagnostic performance does serum AKR1B1 show for CMT?\",\"answer\":\"Serum AKR1B1 is significantly higher in canines with CMT than in healthy controls, and ROC analysis reports an AUC of 0.8386 with sensitivity 74.0% and specificity 83.9% at a 3.08 ng/mL cutoff.\"}]","AKR1B1 promotes canine mammary tumorigenesis via activation of PI3K/AKT signaling and acts as a serum biomarker | PDF",1790121969,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0d5a851cdd6541e36b863e7a2b629627.webp",983,1291,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ee1ee00c07c762878fd7d1bd766eea66.webp",982,1290,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/12df89e719bfd209c800a435776f3b9c.webp",981,1289,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e06615a32ad46c482d0ffb9a6257e9e9.webp",980,1287]